Brought to you by 
Sanofi Pasteur, CureVac, In-Cell-Art enter infectious disease vaccine collaboration
08 Dec 2015
Executive Summary
Sanofi Pasteur (and its Sanofi Pasteur VaxDesign Corp. division), CureVac GMBH (mRNA-based vaccines), and In-Cell-Art SAS (nanocarriers for drug delivery) have entered into a four-year sponsored research collaboration that involves potential licensing of resulting infectious disease vaccines.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi Pasteur, CureVac, In-Cell-Art enter infectious disease vaccine collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice